argenx to Present at the 42nd Annual Cowen Health Care Conference
February 28, 2022 – argenx (Euronext & Nasdaq: ARGX) announced its participation in the 42nd Annual Cowen Health Care Conference on March 7, 2022, at 2:10 p.m. E.T.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
February 28, 2022 – argenx (Euronext & Nasdaq: ARGX) announced its participation in the 42nd Annual Cowen Health Care Conference on March 7, 2022, at 2:10 p.m. E.T. Management will engage in a fireside chat during the event. Interested parties can access a live webcast via the Investors section of the argenx website, with a replay available for 90 days after the presentation. argenx specializes in creating innovative therapies for severe autoimmune diseases.
Details
News Market Reaction – ARGX
The recorded move for ARGX in the trading session of this news was +0.48%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
February 28, 2022
Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in a fireside chat at the 42nd Annual Cowen Health Care Conference on Monday, March 7, 2022 at 2:10 p.m. E.T.
A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately 90 days following the presentation.
About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first-and-only approved neonatal Fc receptor (FcRn) blocker in the U.S. and Japan. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Twitter, and Instagram.
For further information, please contact:
Media:
Kelsey Kirk
kkirk@argenx.com
Joke Comijn (EU)
jcomijn@argenx.com
Investors:
Beth DelGiacco
bdelgiacco@argenx.com
Michelle Greenblatt
mgreenblatt@argenx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.